One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
ADiTx Therapeutics logo
ADiTx Therapeutics ADTX
report update icon

Quarterly report 2026-Q1
added 11-21-2026

ADiTx Therapeutics Cash Flow 2025-2011 | ADTX

Brief overview of ADiTx Therapeutics's cash flow quality

The review uses the five latest available annual reports between 2021 and 2025.

The latest year produced an operating outflow of -$25.7 million. A return to positive cash generation is important.

Operating cash flow was positive in only 0 of five periods. Cash generation remains unstable.

Overall picture

Taken together, ADiTx Therapeutics's cash flow indicators point to increased dependence on reserves or outside financing.

Annual Cash Flow ADiTx Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-25.7 M -16.8 M -19.2 M -22.4 M -22.3 M -7.22 M -464 K - - - - - - - -

Depreciation & Amortization

269 K 614 K 435 K 429 K 369 K 17.8 K - - - - - - - - -

Accounts Payables

7.34 M 10.2 M 7.52 M - - - - - - - - - - - -

Accounts Receivables

- 122 K 408 K 528 K 89.8 K - - - - - - - - - -

Total Inventories

5.77 K 11.2 K 746 K 950 K - - - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow ADiTx Therapeutics

2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-4.58 M -9.25 M -2.34 M -2.38 M -11.7 M - -2.36 M -2.29 M -5.96 M -3.94 M -8.03 M -3.28 M -3.95 M -6.72 M -7.82 M -2.65 M -5.2 M -8.69 M -4.53 M -5.01 M -4.05 M -3.15 M -4.07 M -406 K -251 K - -415 K -309 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

834 833 833 834 833 - 833 833 833 27.3 K 26.8 K 26.8 K 26.8 K 26.8 K 26.8 K 26.8 K 26.8 K 27 K 27 K 26.7 K 26.4 K 15 K 2.8 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

7.73 M 7.34 M 10.4 M 9.68 M 6.65 M 971 K 1.13 M 668 K 413 K 7.52 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Receivables

12 K - 39.2 K 39.7 K 42.1 K 43.4 K 352 K 407 K 427 K 408 K 363 K 379 K 329 K 528 K 663 K 411 K 249 K 89.8 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Inventories

128 K 5.77 K 6.57 K 7.62 K 9.06 K 11.2 K 89 K 566 K 623 K 746 K 858 K 1.02 M - 950 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company ADiTx Therapeutics, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Provention Bio Provention Bio
PRVB
- - $ 2.37 B usaUSA
Reata Pharmaceuticals Reata Pharmaceuticals
RETA
- - $ 6.29 B usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
$ 0.47 -24.53 % $ 305 K israelIsrael
iTeos Therapeutics iTeos Therapeutics
ITOS
- - $ 411 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 1.44 -2.03 % $ 2.37 M israelIsrael
PolarityTE PolarityTE
PTE
- -0.82 % $ 1.78 M usaUSA
Kronos Bio Kronos Bio
KRON
- 1.49 % $ 50.8 M usaUSA
Cullinan Management Cullinan Management
CGEM
$ 8.9 -1.93 % $ 536 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 39.15 0.57 % $ 3.52 B schweizSchweiz
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Stoke Therapeutics Stoke Therapeutics
STOK
$ 26.77 -0.59 % $ 1.59 B usaUSA
Trevena Trevena
TRVN
- -46.58 % $ 31.8 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Molecular Templates Molecular Templates
MTEM
- -23.43 % $ 495 K usaUSA
Oncorus Oncorus
ONCR
- -8.54 % $ 3.19 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 0.07 9.81 % $ 855 K usaUSA
Novan Novan
NOVN
- -24.84 % $ 2.64 M usaUSA
CohBar CohBar
CWBR
- -15.44 % $ 2.2 M usaUSA
NeuBase Therapeutics NeuBase Therapeutics
NBSE
- -1.56 % $ 12.3 M usaUSA
Epizyme Epizyme
EPZM
- - $ 249 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Scopus BioPharma Scopus BioPharma
SCPS
- -48.37 % $ 3.71 M usaUSA
Nabriva Therapeutics plc Nabriva Therapeutics plc
NBRV
- - $ 4.55 M irlandaIrlanda
Annovis Bio Annovis Bio
ANVS
$ 0.71 -3.81 % $ 14.6 M usaUSA
scPharmaceuticals scPharmaceuticals
SCPH
- - $ 218 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
- - $ 105 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Global Blood Therapeutics Global Blood Therapeutics
GBT
- - $ 4.62 B usaUSA
Inozyme Pharma Inozyme Pharma
INZY
- - $ 207 M usaUSA
NanoString Technologies NanoString Technologies
NSTG
- -37.43 % $ 5.1 M usaUSA
Humanigen Humanigen
HGEN
- -81.12 % $ 4.28 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 3.56 -9.07 % $ 1.58 M usaUSA
Sorrento Therapeutics Sorrento Therapeutics
SRNE
- -29.58 % $ 126 M usaUSA
Surface Oncology Surface Oncology
SURF
- - $ 59.7 M usaUSA
Sierra Oncology Sierra Oncology
SRRA
- -0.05 % $ 1.34 B canadaCanada
Vaccinex Vaccinex
VCNX
- -61.37 % $ 654 K usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
- -19.68 % $ 18.4 M canadaCanada
Jounce Therapeutics Jounce Therapeutics
JNCE
- - $ 98.4 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 0.93 -4.11 % $ 10.5 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 1.89 6.78 % $ 52.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Longeveron Longeveron
LGVN
$ 1.65 -9.34 % $ 29 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Immunic Immunic
IMUX
$ 7.0 -5.28 % $ 1.09 B usaUSA
Immunovant Immunovant
IMVT
$ 31.74 -2.4 % $ 5.79 B usaUSA
Mersana Therapeutics Mersana Therapeutics
MRSN
- - $ 3.56 B usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 6.83 1.71 % $ 460 B britainBritain
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain